Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials. Recently, the crystal structures of PD-L1 in complex wit...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Lee, Hyun Tae, Lee, Ju Yeon, Lim, Heejin, Lee, Sang Hyung, Moon, Yu Jeong, Pyo, Hyo Jeong, Ryu, Seong Eon, Shin, Woori, Heo, Yong-Seok
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5514103/
https://ncbi.nlm.nih.gov/pubmed/28717238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-06002-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak